Rapid tumor development and potent vascularization are independent events in carcinoma producing FGF-1 or FGF-2

Clotilde Billottet1, Bassam Janji, Jean-Paul Thiery

  • 1Laboratory of Cell Morphogenesis and Tumor Progression, UMR 144 CNRS, Institut Curie, Section de recherche, 26 rue d'Ulm, 75248 Paris, cedex 05, France.

Oncogene
|November 22, 2002
PubMed

Insights

Autocrine fibroblast growth factors (FGF-1, FGF-2) promote tumor invasion and tumorigenicity by activating fibroblast growth factor receptors (FGFRs). Basal angiogenesis, not increased vascularization, supports rapid tumor development.

Area of Science:

  • Oncology
  • Cell Biology
  • Molecular Biology

Background:

  • Fibroblast growth factors (FGF-1, FGF-2) are key regulators of cell behavior via fibroblast growth factor receptors (FGFRs).
  • Understanding the distinct roles of autocrine versus non-autocrine FGF signaling is crucial for cancer research.

Purpose of the Study:

  • To investigate the role of autocrine FGF-1 and FGF-2 signaling in tumor progression.
  • To differentiate the effects of autocrine and non-autocrine cellular activity on tumor cell phenotype and behavior.

Main Methods:

  • Engineered rat bladder carcinoma NBT-II cells to produce FGF-1 or FGF-2 with or without FGFRs.
  • Assessed cell phenotype (epithelial vs. mesenchymal), in vitro invasion, in vivo tumorigenicity, and vascularization.
  • Quantified urokinase plasminogen activator receptor (uPAR) and active urokinase plasminogen activator (uPA) expression.

Main Results:

  • Autocrine cells (producing FGF and expressing FGFRs) exhibited a mesenchymal phenotype, high invasiveness, and tumorigenicity.
  • Non-autocrine cells (producing FGF but lacking FGFRs) retained an epithelial phenotype.
  • Tumors from autocrine cells showed increased uPAR/uPA and vascularization, but rapid tumor growth was independent of enhanced vascularization, suggesting basal angiogenesis is sufficient.

Conclusions:

  • Autocrine FGF signaling, through FGFR activation, drives invasive and tumorigenic properties.
  • FGF-1 and FGF-2 do not show differential functions in this model.
  • Tumorigenesis can progress rapidly with basal angiogenesis, independent of FGF-induced angiogenic stimulation.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...